248 products were found matching "K05099"!

Protein function: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces...

JNJ-26483327 is an inhibitor of Met. It also inhibits EGFR, HER2, and HER4 (IC50s = 9.6, 18, and 40.3 nM, respectively). JNJ-26483327 (5 or 10 µM), in combination with trastuzumab, reduces HER2 phosphorylation in BT474 breast cancer cells. It decreases tumor volume when used in combination with trastuzumab in a...

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGF R), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which...

et, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGF R), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are...

INCB 28060 is an inhibitor of heptatocyte growth factor receptor (HGFR, also known as c-Met), potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM). It blocks cell proliferation and migration or induces apoptosis...

The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor, have been implicated in the development and progression of several human cancers. PHA-665752 is an ATP-competitive, active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM, IC50 = 9 nM). It exhibits >50-fold selectivity...

Foretinib is a broad-spectrum tyrosine kinase (TK) inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRbeta, and Tie-2, at nanomolar concentrations. It blocks HGF-induced Met phosphorylation and VEGF-induced ERK phosphorylation, preventing HGF-induced responses in...

(R)-Crizotinib is a dual inhibitor of c-Met and anaplastic lymphoma kinase (ALK, IC50s = 8 and 20 nM, respectively, in a cell-based assay). It is selective for c-Met and ALK over several other receptor- and non-receptor tyrosine kinases, including Ron, Tie2, Abl, LCK, and VEGFR2 (IC50s = 0.08, 0.448, 1.159, 2.741,...

AMG 337 is an orally active and selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways. It has been shown to inhibit hepatocyte growth factor-mediated c-Met phosphorylation in PC3 cells (IC50 = 5 nM) and to...

The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer. SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM. It is over 1,000-fold selective for c-Met over a panel of other kinases....

NPS 1034 is a dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM), receptors for hepatocyte growth factor and vitamin K-dependent proteins, respectively. It synergistically inhibits cell proliferation when used in combination with gefitinib (Cay-13166) or...

Glumetinib is a potent inhibitor of c-Met (IC50 = 0.42 nM). It is greater than 2,400-fold selective for c-Met over a panel of 312 kinases. Glumetinib (0.001-1 µM) inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells. It inhibits NCI H441 cell motility...